Agenda items scheduled for review by the PBAC under the process for reviewing recommendations not accepted by applicants

MAESTrO Database

13 May 2021 - The revised agenda for the July 2021 PBAC meeting notes seven medicines/medicinal preparations for review under the new process.

The seven medicines/medical preparations are:

  • Budesonide - March 2019
  • Enoxaparin sodium - July 2020
  • Ramucirumab - March 2018
  • Secukinumab - March 2016
  • Sevelamer carbonate - November 2017
  • Tenofovir alafenamide fumarate - March 2017
  • Triglycerides - medium chain (Nutrini Peptisorb) - March 2019

The list is odd given it includes medicines recommended more than five years ago and omits others recommended in more recent times.  The list does not include the recommendations for:

  • Sarilumab - November 2018
  • Pegfilgrastim - March 2018
  • Ranolazine - March 2018

There are many more.

The inclusion for ramucirumab seems odd given the PBAC's rejection of Eli Lilly's resubmission in July 2019.  The Committee did not recommend a change to the basis of its March 2018 recommendation for ramucirumab for use in combination with paclitaxel for the treatment of patients with gastric or gastro-oesophageal junction adenocarcinoma.


Michael Wonder

Posted by:

Michael Wonder